Brinton raises $4 million from Tata Capital

BENGALURU: Brinton Pharmaceuticals, which provides healthcare products and services for various therapeutic segments, has raised $4 million (approx Rs 25.6 crore) from Tata Capital Healthcare Fund, as the firm looks to enter into newer areas such paediatrics and gynaecology and expand its international operations.

"Our plan is to enter into paediatric and gynaecology (segments).The funding will be used to enter these two areas. We will be adding 200 people for our paediatric section," said Rahul Darda, managing director of Brinton Pharma.

Brinton, which is already into dermatology and cosmeceuticals, is betting big on these fast-growing therapeutic segments in the Indian pharma market, which is growing at a CAGR of 15%.

"A long-term impact in the field of R&D will make newer innovations in the field of dermatology possible," said Darda.

"After evaluating the opportunities in the market, adjusted for relative valuation, we concluded that we would be better served to invest in small and mid-sized businesses seeking growth capital, sharply focusing on key growing niche therapies. Brinton offered us that opportunity as we viewed it as a company promoted by a young entrepreneur whose family had roots in the pharma business," said Visalakshi Chandramouli, partner, Tata Capital Healthcare Fund.